Fund+

Fund+ invests in innovative life sciences companies, primarily focusing on therapeutics, diagnostics, and medical devices. They target companies seeking Series A or B financing that have already achieved Proof of Concept (POC). The fund aims to generate both attractive financial returns and a positive societal impact, contributing to a sustainable improvement in the biotech ecosystem. Fund+ operates as an open-ended fund for long-term equity investments, with a particular emphasis on companies within Belgium. Their mission is to create sustainable shareholder value, support the development of a leadership position within the Life Sciences sector, and generate a tangible, beneficial societal impact. The firm's origin stems from the collaboration between the private foundation Désiré Collen and the non-profit organization Life Sciences Research Partners in May 2015. Fund+'s investment approach is guided by a commitment to long-term vision and societal values, shared by its diverse investor base, including high net worth individuals, family offices, and governmental agencies. They typically invest between 5 and 15 million euros per company, spread across various milestones. The firm is legally structured as a Belgian Naamloze Vennootschap/Société Anonyme (NV/SA) and is based in the Groot Begijnhof of Leuven, a designated World Heritage Site.

therapeutics, diagnostics, medical devices

Thematische Schwerpunkte und Zielmarktsegmente von Interesse.